{'fraction_non_alphanumeric': 0.03297096266628522, 'fraction_numerical': 0.02767844371334573, 'mean_word_length': 4.950212765957446, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Outcomes of pregnancies with trisomy 16 mosaicism detected by NIPT: a series of case reports

Background Trisomy 16 (T16) is thought to be the most frequent chromosome abnormality at conception, which is often associated with a high risk of abnormal outcomes. Methods A retrospective analysis of 14 cases with high risk of T16 by noninvasive prenatal testing (NIPT) was conducted. All cases in the analysis involved prenatal diagnosis, karyotyping and chromosomal microarray analysis. Case reports NIPT detected 12 cases of T16 and 2 cases of T16 mosaicism. Prenatal diagnosis confirmed 5 true positive cases and 9 false positive cases. Among the 5 true positive cases, 3 cases had ultrasound abnormalities. All of the 9 false positive cases continued their pregnancies. The newborns who were from these 9 false positive cases except 1 case (case 7) had low birth weights (< 2.5 kg) and there were also 2 premature deliveries. Conclusion NIPT serves as a fast and early prenatal screening method, giving clues to chromosome abnormalities and providing guidance for managing pregnancy. Confined placental mosaicism in 16 pregnancies may be at higher risk for preterm delivery.


Introduction
In 2011, noninvasive prenatal testing (NIPT) was introduced to clinical practice, and the application of this technology has continuously evolved. Recently, researchers have started to focus on sharing their experience with expanded NIPT and discussing the outcomes of rare autosomal trisomies (RAT, defined as any autosomal trisomy other than T21, T18, and T13). Trisomy 16 (T16) is of particular importance as it is thought to be the most frequent chromosome abnormality at conception [1], with an incidence of ~ 1.5% [2]. Complete T16 is incompatible with life, while viable mosaic trisomy 16 (MT16) has been reported extensively in the literature [3,4]. Almost all pregnancies which involve MT16 originate from a trisomy 16 zygote because of maternal meiosis I nondisjunction [5]. As with many trisomic conceptuses, trisomy 16 mosaicism can undergo rescue, with the risk of residual mosaicism and uniparental disomy (UPD) for chromosome 16 in the surviving fetus. UPD is the inheritance of both homologs of a chromosome from only one parent with no representative copy from the other parent, and UPD 16 is the most common [6].
In addition to UPD, other factors that may contribute to the pathogenesis of trisomy 16 mosaicism are (1) the degree of trisomy in various tissues of the placenta and fetal membranes; (2) the degree and distribution of trisomy in tissues of the fetus; and (3) the sex of the fetus [7].
MT16 is most likely associated with adverse perinatal outcomes, such as a high risk of abnormal outcomes, intrauterine growth retardation (IUGR), fetal death in utero, preeclampsia, preterm delivery, neonatal death, developmental delay, congenital heart defects, and other anomalies [4]. Thus, a detailed account of the detection of trisomy 16 is essential for numerous prenatal testing modalities. In this paper, we report a series of new cases of T16, perform a careful prenatal cytogenetic diagnosis for patients and provide more knowledge for reference about T16 and prenatal diagnoses for clinicians.

Detection of NIPT
Whole blood samples of 5 to 10 ml from pregnant women were collected in EDTA tubes and processed according to the following procedures after collection within 8 h. Afterwards, cfDNA extraction, library construction, quality control, and pooling were performed by means of JingXin Fetal Chromosome Aneuploidy (T21, T18, and T13) Testing Kits (CFDA registration permit No. 0153400300). Then, the JingXin Bio-electronSeq 4000 System (CFDA registration permit NO. 20153400309), a semiconductor sequencer, was used for DNA sequencing. Sequencing reads were filtered and aligned to the human reference genome (hg19) [8]. Fetal and maternal chromosome copy number variations (CNVs) were classified with our modified Stouffer's z-score method as described previously [9]. Additionally, an absolute Z-score greater than 3 was marked with chromosome aneuploidies or microdeletions/microduplications.

Prenatal diagnosis
NIPT high-risk cases were advised to undergo invasive prenatal diagnosis, including chromosome karyotype analysis and chromosomal microarray analysis (CMA). Metaphase chromosome G-banding karyotyping was performed at a level of 320 to 400 bands. CMA was performed for amniotic fluid or cord blood. Fetal genomic DNA was amplified, labeled, and hybridized by using the CytoScan 750 K array platform (Affymetrix, USA) according to the manufacturer's protocol. Data were visualized by scanning with CytoScan ™ and analyzed with Chromosome Analysis Suite software (Affymetrix, USA) based on the GRCH37 (hg19) assembly.

NIPT and prenatal diagnosis results
A total of fourteen chromosome 16 abnormalities cases predicted by NIPT were included in this study. The age of the pregnant women was 23-43 years, and the gestational week was 13-25 weeks. The Z score of Chr. 16 was from 7.791-31.503, and the NIPT results predicted 12 cases of T16 and 2 cases of T16 mosaicism. The physician suggested that all high-risk pregnant women undergo prenatal diagnosis, including karyotyping and CMA. Prenatal diagnosis revealed 5 true positive cases (cases 1-5) and 9 false positive cases (cases [6][7][8][9][10][11][12][13][14]. It is worth mentioning that cases 1-5 had T16 predicted by NIPT, but prenatal diagnosis confirmed that they had T16 mosaicism. The  (Table 1).

Pregnancy outcomes
Among the 5 true positive cases, case 1 insisted on continuing her pregnancy. Ultrasound examination suggested that case 1 had intrauterine growth restriction, a persistent right umbilical vein, and abnormal umbilical blood flow. In case 1, the baby was born with a low birth weight of 1.9 kg, and there were no other abnormalities by newborn screening. Both the karyotype and CMA showed T16 mosaicism in case 2. A three-stage ultrasound scan was carried out at 30 gestational weeks, and the results showed small limbs, a cardiac defect, and inconsistency with the gestational age. Further echocardiography examination showed total anomalous pulmonary venous drainage (TAPVD), a ventricular septal defect (VSD), and a left aortic arch with right descending aorta (Fig. 1). The parents were determined to continue the pregnancy. A male newborn was delivered by cesarean section at 37 gestational weeks. However, the infant died due to congenital heart disease 13 days after birth. In case 3, T16 mosaicism was confirmed. A prenatal three-stage ultrasound scan showed a butterfly vertebral anomaly in T3. At 30 gestational weeks, the pregnant woman underwent an MRI scan, which showed the same abnormality as the ultrasound result. The pregnancy was terminated. T16 mosaicism was also confirmed in case 4. The karyotype of the parental peripheral blood was normal. This pregnancy was also terminated. Case 5 was confirmed to have LOH at 16p13.3-p12.3 and 16q23.3-q24.3, and the fetus died in utero (Table 2). Among the 9 false-positive cases, all the pregnancies continued, and all babies, except in case 7, were born with low birth weights (< 2.5 kg). There were two premature deliveries, which suggested that trisomy 16 pregnancies may be at higher risk for preterm delivery. In addition, the baby in case 8 showed cerebral edema and anemia during newborn screening, and the mother had preeclampsia. The women in cases 13 and 14 delivered premature babies ( Table 2).

Discussion
Trisomy 16 is one of the most frequently encountered rare autosomal abnormalities in first-trimester abortion. Complete trisomy 16 is not compatible with life, so almost all cases of trisomy 16 are mosaic type. Fetuses with trisomy 16 mosaicism are viable and reported extensively in the context of prenatal diagnosis, but trisomy 16 mosaicism is associated with adverse pregnancy outcomes [7,10]. For clinical counseling, it is essential to detect trisomy 16 mosaicism accurately.
The vast majority of chromosomal abnormalities can be detectable in the first trimester. Over the last few decades, with the development of technique, the classical combined first trimester test, screening for common chromosomal abnormalities at first trimester improved with more than 90% detection rates and 3-5% false positive rates, it is considered as "gold standard". However, the introduction of noninvasive prenatal testing challenged this situation [11]. It is reported that NIPT had a detection rate about 99% and a false positive rate < 0.1% when screening for trisomy 21, 18, and 13 [12]. From 2015 to 2019, 44,423 pregnant women underwent NIPT tests in our prenatal diagnostic center, with a total false positive number of 66 and a total false negative number of 2. NIPT used in this study was performed by a semiconductor sequencing platform (SSP); the overall sensitivity and specificity of this platform for detecting trisomy 21, 18, and 13 combined were 99.61% and 99.91%, respectively [8].
Moreover, NIPT can offer information on other chromosomal abnormalities. Recent research proves that the ability of First trimester screening (FTS) to screen rare chromosomal abnormalities is poor [13]. Thus, as a fast, more accurate, and non-invasive method, NIPT would be preferred among patients. NIPT based on cell-free DNA is a new sequencing technique. It is available for use in pregnancies with a gestational time of 12 weeks or higher. In the present study, the earliest gestational NIPT to predict a high risk of T16 was performed at 13 weeks, which meant that NIPT could serve as a fast and early prenatal screening tool to provide information about chromosome abnormalities.
A previous study reported that the birth weights of live births from mosaic trisomy 16 pregnancies were below the gestational age-corrected mean birth weights in the general population [7,14]. In our study, a true mosaic trisomy 16 pregnancy was continued, and the baby was born with a weight of 1.9 kg, which is low birth weight compared to average. Of the 9 false positive cases, all the pregnancies were continued, and all infants, except case 7, were born with low birth weights. This indicates that some level of below-average growth is a nearly universal phenomenon in trisomy 16 mosaicism and supports the hypothesis of undetected trisomy mosaicism as an etiological factor in both severe and mild idiopathic intrauterine growth restriction. In addition, there were 2 premature babies in this study, which suggests that trisomy 16 pregnancies may be at higher risk for preterm delivery. Further research is needed to determine whether there is truly a higher risk of preterm delivery in an unbiased population.
Cell-free DNA comes from the apoptotic cells of cytotrophoblasts, so the NIPT result shows a high risk of trisomy 16, indicating some trisomic cells in the placenta. It is recognized that the primary source of false positive results are confined placental mosaicism (CPM). CPM is a type of chromosomal mosaicism in which chromosome abnormalities are present in chorionic villi/placenta but not in the fetus itself. In our study, 9 cases were false positive, and we highly suspected that the CPM caused these. However, this study was a retrospective study, and all pregnancies had been completed. We could not obtain placental samples to verify our speculation, which was a limitation of our research. T16 was associated with poor outcomes [15]. Diane Van O and colleagues found that cases with abnormal NIPT T16 results most likely caused by placental aberrations manifest mostly as IUGR or small for gestational age (SGA) [16]. Another study by Yi H et al. showed that IUGR could be found in 20% of CPM cases for T16 detected by NIPT with placenta evidence [17]. In our series of cases, all false positive cases, except case 7, were low-birth-weight babies. We speculated that low birth weight was also related to CPM. However, more samples are needed for verification, which will also be one of our future research directions. NIPT detected T16 or T16 mosaicism in this present study, with a true positive rate of 35.7% (5/14). In recent years, many studies have reported NIPT screened for other chromosome aneuploidy [18], but the PPVs for other chromosome aneuploidy were relatively low [19]. On one hand, these aneuploidies are less prevalent. On the other hand, many of them have high CPM. In CPM cases, the cytogenetic abnormality is confined to the placenta. Thus, CPM of T16 presents karyotype discordance between fetus and placenta. [20]. If there are placental samples to verify NIPT, it would be better. But in this retrospective study, we cannot obtain a placenta sample, which is a shortcoming of our ability to investigate this phenomenon.
Pregnant women choosing NIPT should be well informed of the accuracy, reliability, false-positive and false-negative rates. In addition, NIPT is a screening test, American College of Medical Genetics and Genomics (ACMG) is strongly suggested to confirm by invasive prenatal diagnosis for all positive findings [21]. Although IUGR or small for gestational age is a universal phenomenon in trisomy 16 mosaicism and CPM, the long-term neurodevelopment outcomes were reported favorable [22]. In this research, the outcome of 9 false positive cases is better than true trisomy 16 mosaicism cases, which means if confirmed tests were negative, the outcome might be promising. T16 CPM needs to be monitored closely for obstetric and neonatal complications. Results of MT16 should be delivered in a timely, objective, and nondirective manner for parents to make a decision.
In conclusion, trisomy 16 mosaicism is complex. NIPT serves as a fast and early prenatal screening method to give clues to chromosome abnormalities, guiding pregnancy management. Combined cytogenetic techniques and molecular methods can accurately detect trisomy 16 mosaicism. Confined placental mosaicism in T16 pregnancies may be at higher risk for preterm delivery.